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ABSTRACT
The unfavourable outcome of amyotrophic lateral sclerosis (ALS) confronts patients with challenging decisions regarding 
life-sustaining measures. The decision-making process is usually triggered by medical consultations and patient-dependent 
factors. This may largely depend on the physician’s depth of knowledge and professional experience. 
This paper presents an overview of the life-sustaining methods used in ALS and their effects on disease progression, survival and 
quality of life of patients and their caregivers. It is intended to aid physicians in their discussions with patients. We interrogate 
all the positive and negative facets of life-sustaining measures that may allow for optimisation of the decision-making process 
and care provision.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neu-
rodegenerative disease primarily involving the motor neuron 
cells in the brain and spinal cord. It is clinically characterised 
by muscle weakness and wasting which leads to quadriparesis, 
usually accompanied by impairments of speech and swallowing. 
Respiratory failure, which develops over the course of the disease, 
leads to death within 2-5 years of initial symptoms onset [1]. 
There are only two registered drugs to modify survival 
(riluzole) and disease progression (edaravone, but only in 
a subgroup of patients). Thus, most ALS patients require the 
support of medical devices at advanced stages, including per-
cutaneous endoscopic or radiologically inserted gastrostomy 
(PEG/RIG), non-invasive (NIV) or invasive ventilation (IV) 
[2]. These methods may affect patients’ physical and psycho-
logical integrity. The decision-making process reflects several 
factors including the patient’s personal values, relations with 
caregivers, social support, economic situation, and a feeling 
of being a burden to one’s family [3, 4, 5]. To ensure the 
provision of satisfactory care, the discussion during medical 
consultation should focus on the benefits, risks, constraints, 
and consequences of each life-sustaining method.
Beside halting disease progression and prolonging life, the 
fundamental goal of the management of ALS is to maintain 
or improve quality of life (QoL) [6]. According to the World 
Health Organisation (WHO), QoL comprises health-related 
factors such as physical, functional, emotional, and mental 
well-being, as well as non-health-related factors such as jobs, 
family, friends, and spirituality [7, 8]. Although almost two-
thirds of ALS patients declare ‘health’ to be a relevant domain 
of their QoL, the self-generated ratings describe a range of cat-
egories beyond physical and functional impairment [9]. These 
include the support of caregivers as well as existential and 
psychological factors [9–14]. Moreover, despite the relentless 
progression of physical disabilities, no significant correlation 
between functional performance and QoL has been found in 
patients with ALS [4, 9–11, 15, 16]. Thus, non-health-related 
factors appear to play an important role in determining an 
ALS patient’s well-being.
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In this paper, we summarise the literature on the use of 
gastrostomy, NIV and IV in ALS patients with respect to 
each treatment’s impact on disease progression, survival, and 
overall QoL of ALS patients and caregivers. Our aim is to aid 
physicians in their discussions with patients. We believe that 
thorough discussion of the positive and negative aspects of 
life-sustaining measures will allow for optimisation of the 
decision-making process and care provision.
Enteral nutrition
Weight loss in ALS 
Weight loss is a common feature in ALS, seen in c.16–56% 
of patients [17, 18, 19]. It is not solely attributable to dyspha-
gia, as symptoms of impaired swallowing are absent in 40% 
of malnourished patients [17]. Higher energy expenditure 
results from increased respiratory effort, muscle fasciculation, 
hypermetabolism, decreased food intake caused by a loss of 
appetite, hypogeusia, fatigue, depression, inadequate caloric 
intake, and constipation due to decreased physical activity 
[17, 20–22]. Malnourishment itself further induces skeletal 
muscle wasting, fatigue, and an altered pattern of muscle 
contraction and relaxation [23, 24]. All of these affect QoL, 
which may further impair food intake and loss of weight in 
a ‘vicious cycle’ [23].
Indication and methods
The primary management of dysphagia involves support 
techniques, including a correct upright eating position, adjust-
ing dentures, thickening of liquids and blending/softening of 
solid foods, along with providing small, high-calorie, frequent 
meals [6, 25]. Enteral tube nutrition should be considered if 
weight continues to decrease despite these measures.
The procedures include a percutaneous endoscopic gas-
trostomy (PEG) and a percutaneous radiologic gastrostomy 
(PRG), also known as a radiologically inserted G-tube. A naso-
gastric tube is an option only for a short period because it is 
uncomfortable and can lead to oesophageal ulcers [25, 26]. 
Determining the optimal time for starting enteral nutrition is 
challenging. Physicians should consider both the nutritional 
and respiratory status of the patient. Symptomatic dysphagia, 
dehydration, prolonged or curtailed meals due to choking, 
a BMI of < 18–18.5 or a loss of weight of more than 10% or 
even as little as 5% of the premorbid value indicate the need 
for enteral tube feeding (PEG or PRG) in ALS patients [19, 25, 
27, 28]. The objective is also to minimise the risk of perioper-
ative complications (i.e. aspiration pneumonia or respiratory 
insufficiency). Therefore, it is recommended to perform the 
procedure when the predicted FVC value is still > 50% [25, 
29, 30]. Although a lower FVC is not a contraindication for 
PEG/RIG, the procedure should be performed with caution 
[25, 29]. For a summary of indications for gastrostomy tube 
feeding, see Table 1.
In ALS patients, PEG is used more widely than other meth-
ods for enteral feeding [27]. PRG was initially recommended in 
patients with slow vital capacity < 50% due to a higher success 
rate and a lower rate of major complications [31, 32, 33, 34]. 
Further studies (by Shaw et al. and the ProGas study) have 
shown a comparable safety profile between PEG and PRG [27, 
35, 36]. In order to increase safety, the use of NIV before or 
during the procedure should be considered if PEG insertion is 
planned in patients with respiratory symptoms [37, 38]. Except 
for pain at the site of gastrostomy (more common in patients 
undergoing PEG), there are no significant postoperative dif-
ferences between the RIG and PEG methods [39]. Generally, 
the choice of method of enteral tube feeding should be based 
on the experience of a local centre [6, 25]. 
Due to the more frequent use of PEG than of PRG in 
ALS patients, further topics are discussed below based on the 
literature concerning PEG.
Provision of PEG
The provision of enteral nutrition depends on the health-
care system [40]. An analysis of both sociodemographic and 
disease indicators in a group of 121 patients showed that 
a baseline preference for PEG was the strongest predictor for 
later opting for this measure [41]. In addition, discussing PEG 
with a clinician experienced in the field of nutrition signifi-
cantly increases patients’ positive decision rate regarding PEG 
insertion [42]. A similar effect is seen in patients following 
a meeting with a professional home care team [3, 43]. 
Effect of PEG on weight and survival
Loss of weight and a low BMI are well-known predictors 
of shorter survival in ALS [17, 18, 44, 45, 46]. The risk of death 
is 3.5 to 7.7-fold higher in malnourished ALS patients [18, 
Table 1. Indications for PEG administration in patients with ALS
Indications References
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BMI — Body Mass Index; FVC — Forced Vital Capacity
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19]. Numerous reports have shown that patients with PEG 
maintain, or even increase, their total body weight [17, 19, 28, 
30, 42, 47, 48, 49]. This is especially important because there 
is evidence of slower disease progression in individuals with 
a BMI of 30–35 [46, 50, 51].
Mean survival following PEG insertion ranges between 
122 and 393 days. The mortality rates are below 3.6% and 11.5% 
at 24 hours and 30 days, respectively [28, 30, 52, 53]. Forbes 
reported survival rates of 46% (39% for limb-onset and 51% 
for bulbar-onset) and 23% (17% for limb-onset and 27% for 
bulbar onset) six months and 12 months after the procedure, 
respectively [54]. Although there is no difference in survival 
among patients according to the use of PEG or RIG, patients 
on nasogastric tube feeding demonstrate significantly shorter 
survival [32, 35, 39]. 
PEG does not prevent aspiration. Risk factors for aspira-
tion during PEG include previously experienced aspiration 
pneumonia, evidence of reflux oesophagitis at the time of 
endoscopy, older age, male gender, diabetes, and the presence 
of infection [30].
Multiple studies have investigated an association between 
the FVC% at the time of PEG insertion and the post-PEG 
survival time. The implementation of PEG results in a longer 
survival in ALS patients as long as the FVC exceeds 38% of 
the predicted value [29]. Most studies have reported a signifi-
cantly longer survival in patients with FVC > 50% compared to 
FVC < 50% of the predicted value [28, 30, 55]. However, both 
groups showed longer survival when compared to patients 
who refused PEG placement [28]. Two publications have 
reported a longer post-PEG survival in patients with FVC of 
65–70% of predicted value compared to FVC of 50–65% [47, 
56]. Death within 30 days following PEG introduction has 
also been reported to occur more commonly in patients with 
a decreased predicted volume of FVC (< 50%) and decreased 
serum chloride [30]. 
Determinants of a poor late outcome of PEG include an 
initial weight loss of over 10%, a decreased predicted value of 
FVC (< 50–70%), BMI (< 18kg/m2), long-lasting swallowing 
difficulties prior to the start of PEG, older age, a low bulbar 
score of ALSFRS-R (≤ 5), and concomitant neurobehavioural 
dysfunction [19, 28, 29, 30, 42, 43, 47, 54, 56–59]. Studies on 
the effect of gender have proved inconclusive [29, 42, 60].
Although some reports fail to show a survival benefit, 
they could be biased by methodological issues. A large popu-
lation-based study from Scotland compared 142 PEG patients 
to 1,084 non-PEG patients, and found no difference in the 
median survival between the two groups. However, in this 
cohort, the PEG group was characterised by a significantly 
shorter diagnosis delay (a well-known predictor of poor out-
come in ALS), that was not included in the regression model 
[54]. One study reported an even shorter survival time in the 
PEG group, but the control group consisted of individuals who 
declined the use of PEG as well as some who had no indication 
for parenteral feeding [28]. In a meta-analysis (n = 966) using 
an odds ratio (OD) as the survival rate, a higher mortality in 
patients without PEG compared to the PEG group was found 
only at the 20-month follow-up (OR = 1.97; 95% CI 1.21-3.21, 
p = 0.007); there was no significant difference in the 30-day 
or 30-month rates [61].
A major limitation of studies investigating the effect of 
PEG on survival in ALS patients is the methodological dif-
ficulty. A comparison can only be made with patients who 
refused PEG, with the result that no nutritional surveillance 
was provided for them, or with patients for whom there was 
no indication of PEG, who thus primarily represented a group 
with better outcomes.
Effect of PEG on QoL
Weight loss in patients with ALS is associated with a worse 
self-reported QoL and shows a trend towards a decreased 
mood [17]. In particular, the Vitality domain of SF-36, reflect-
ing exhaustion, tiredness and lack of spirit, has been found to 
strongly relate to weight loss in ALS patients [17].
Surprisingly, only a few studies have explored the effect 
of PEG on QoL in ALS. Mazzini et al. found that patients 
declared an improvement in QoL and better integration into 
social and family environments following PEG insertion; 
however, the paper provided no data [28]. Zamietra et al. 
reported a slight, insignificant decrease in QoL following 
PEG insertion in patients without concurrent use of NIV 
(n = 11); they maintained this score in subjects with concur-
rent use of NIV (n = 5) [62]. In a study involving 13 patients, 
11 (85%) individuals declared an improved QoL following PEG 
insertion, but no patient reported deterioration in QoL [17]. 
Moreover, among individuals in a locked-in state, 90% would 
opt for PEG placement again [16]. Mathus-Vliegen et al. found 
that frequent choking on food and drink significantly impaired 
QoL of patients without PEG compared to those using PEG [52].
Effect of PEG on disease progression
There is no evidence showing that PEG alters disease 
progression in ALS patients. Specifically, Kasarskis et al. re-
ported no effect on ALSFRS-R speech, swallowing, salivation, 
or total score deterioration following PEG insertion [30]. Nor 
was there any effect detected on FVC or SIP [30]. In a six-
month follow-up study, patients using PEG maintained their 
ALSFRS-R score (pre 34.1 ± 8.6 vs post 34.8 ± 7.4, p > 0.05), 
while those without PEG noted a slight drop (33.7 ± 7.9 vs 
31.6 ± 8.8, p > 0.05) [42].
Impact of PEG on caregivers
There is a comparable mean burden for caregivers who 
care for patients with or without PEG (n = 328) [43]. Traila et 
al. reported a similar attitude towards the placement of PEG 
between patients and caregivers: 52% of patients and 58% of 
caregivers endorsed the idea of future PEG placement, 22% 
of patients and 10% of caregivers were uncertain, and 26% 
of patients and 32% of caregivers responded negatively [63]. 
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Table 2. Indications for NIV administration in patients with ALS
AAN 2009 EFNS 2012 NICE 2016 References
Clinical assessment Symptoms and signs of respi-
ratory insufficiency1 
Symptoms and signs of respi-
ratory insufficiency1
Symptoms and signs of respi-
ratory insufficiency1
25, 70, 88, 129, 130, 
131, 132
FVC  < 50%  < 80%
+ 
Symptoms and signs of respi-
ratory insufficiency1
 < 50% 66, 67, 68, 70, 133
Abnormal nocturnal 
oximetry
Yes2 Yes2 - 71, 84, 132
SNIP  < 40 cm H20  < 40 cm H20  < 40 cm H20 133
MIP  < 60 cm H20  < 60 cm H20  < 40 cm H20 70, 71
ABG PaCO2 - > 45 mm Hg > 45 mm Hg 70
SNIP or MIP (+ symptoms 
and signs of respiratory 
insufficiency1)
- - ♂ < 65 cm H20
♀ < 55 cm H20
AAN — American Academy of Neurology; EFNS — European Federation of Neurological Societies; NICE — National Institute for Health and Clinical Excellence; FVC — forced vital capacity; SNIP — sniff nasal-
inspiratory pressure; MIP — maximal inspiratory pressure; ABG PaCO2 — arterial blood gas
1symptoms: daytime sleepiness, dyspnoea, orthopnoea, frequent awakening, morning headaches, daytime fatigue; signs: tachypnoea, use of auxiliary respiratory muscles, paradoxical movement of the abdo-
men, decreased chest wall movement, weak cough, sweating, tachycardia, morning confusion, hallucinations, weight loss, mouth dryness.
2oxygen saturations of less than 90% for 1 cumulative minute; 15 periods of oxygen desaturation per hour; oxygen saturations of less than or equal to 88% for 5 consecutive minutes
Therefore, it is advisable to discuss the need for PEG/PRG 
insertion with both the patient and their caregiver, to facilitate 
the decision process.
Non-invasive ventilation (NIV)
Although respiratory insufficiency is the initial manifes-
tation of the disease in only 2–3% of cases [64], it remains the 
most frequent cause of death in patients with ALS [65]. Breath-
ing failure directly results from inspiratory and expiratory 
muscle weakness, but it may also be due to bulbar dysfunction 
accompanied by aspiration and/or airway obstruction. Impor-
tantly, breathlessness remains a significant source of distress 
to patients with ALS (comparable to pain). Hypoventilation 
leads to sleep disturbances, morning headaches, and fatigue. 
Thus, the use of NIV goes beyond the support of respiratory 
functions: it is a means of pain relief and an effective treatment 
for hypoventilation-induced symptoms. 
Overall, the introduction of NIV in ALS is recommended 
when the FVC is less than 50% of the predicted value, or less 
than 80% in the presence of signs and symptoms of respiratory 
insufficiency [25, 66–70]. It is important to remember that the 
FVC volume is even lower in the supine position (by as much 
as 11%) [71, 72]. Blood gas measurements may be helpful 
in the evaluation of respiratory function in an ALS patient, 
although gas exchange may be well preserved even when the 
FVC decreases to 20% of the predicted value [73]. Measuring 
morning arterial blood gases is especially valuable in individ-
uals with bulbar involvement, in whom spirometry encounters 
technical challenges [25]. A summary of indications for NIV 
is presented in Table 2.
The use of NIV is characterised by a ‘threshold effect’, 
wherein there is a significant reduction in PaCO2 only when 
the use of NIV exceeds four hours per night [74]. Above this 
threshold, there is a dose-dependent effect on gas measure-
ment [74]. Patients with poor adherence, or poor ventilation, 
do not benefit from NIV in any way, and thus a strict follow-up 
prior to discharge of the patient is required to ensure wheth-
er the patient uses the device properly and for the correct 
amount of time [75]. Such compliance is achieved in 49–72% 
of individuals with ALS [68, 76, 77]. The risk of intolerance is 
increased in patients with moderate or severe bulbar symp-
toms, in individuals with low predicted FVC at NIV initiation, 
and in patients with symptoms of cognitive or behavioural 
impairment [57, 68, 76, 77]. 
Despite this, NIV should be introduced to all patients with 
ALS and respiratory insufficiency because there is no study 
that proves that patients with either onset would definitively 
fail to benefit from non-invasive respiratory support [EAN 
guidelines, in preparation]. No effect of age, gender, or disease 
duration has been found [76, 77].
According to the literature, the implementation of NIV can 
be performed either in a hospital setting or an outpatient clinic, 
with a comparable frequency of adverse events and compa-
rable lengths of stay [78, 79]. Although it differs according to 
the healthcare system, NIV initiation at the outpatient clinic 
allows for a significant reduction in the waiting time before 
NIV implementation (13.5 vs 30 days for out- and in-patients, 
respectively, p = 0.04) [78].
Effect of NIV on survival
In a randomised study of patients with orthopnoea and 
PI max < 60% of the predicted value or symptomatic daytime 
hypercapnia, 22 patients assigned to NIV showed a signifi-
cantly higher survival rate (p = 0.0062) relative to 19 patients 
assigned to standard care [80]. Detailed analysis revealed that 
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the significant effect was found in patients with normal or 
moderately impaired bulbar function (p = 0.0059) but not in 
the case of severe bulbar dysfunction (p = 0.92) [80]. In a group 
of patients with bulbar ALS, Pinto et al. reported improved 
one-year (100% vs 88.9%) and three-year survival (87.5% vs 
22.2%) in patients with diurnal abnormalities in gas exchange 
with NIV (n = 10) compared to those without NIV (n = 10) 
[81]. There is no strong evidence for an impact of the site of 
onset on the outcome of NIV, except for patients with severe 
bulbar impairment [80–82].
Lechtzin et al. showed that early implementation of NIV 
in ALS patients (≥ 65% of predicted FVC) resulted in longer 
survival and longer time to tracheostomy from diagnosis com-
pared to patients qualified to NIV at < 65% of predicted FVC 
(2.7 years vs 1.8 years, p = 0.045) [83]. In another study, the 
time to NIV implementation correlated inversely to survival 
with NIV (r = -0.65, p < 0.001) [84]. These results show that 
the early use of NIV increases survival in ALS patients. This 
may be partly due to a greater compliance as achieved at the 
initial stage of respiratory insufficiency [84].
A combination of NIV and PEG shows a trend towards 
longer survival in ALS patients compared to one or the oth-
er applied alone (HR: 0.34, 95% CI 0.10-1.14, p = 0.08 for 
NIV-alone; HR: 0.51, 95% CI 0.21-1.26, p = 0.15 for PEG- 
-alone) [82]. However, this needs to be confirmed in fur-
ther studies, because Zamietra et al. found the same rate of 
ALSFRS-r deterioration in a small group of ALS patients who 
used PEG alone (n = 11), NIV alone (n = 6), and PEG and 
NIV combined (n = 5) [62].
Although there is no difference in the prevalence of NIV 
between patients with and without neurobehavioural dys-
function, the presence of the latter results in reduced survival, 
mainly due to poorer compliance [57].
Effect of NIV on quality of life
Respiratory muscle weakness has a significant influence 
on both sleep-related and non-sleep-related domains of the 
QoL in ALS patients. It shows a greater impact than the overall 
severity of the disease [85, 86]. 
The positive effect of NIV on the QoL in ALS patients has 
been reported in multiple studies. In an up-to-12-month fol-
low-up randomised study (NIV vs normal care), an improve-
ment in the mental component via SF-36 analysis (of mild to 
moderate bulbar-impaired patients) was observed along with 
the symptoms domain of sleep apnoea quality-of-life index 
(SAQLI) (of all patients) [80]. In addition, the improvement 
in health-related QoL (HRQoL) was associated with the use 
of NIV, reaching its peak 3-5 months after the introduction of 
respiratory treatment [80]. In agreement with these findings, 
another study reported an improvement in Epworth Sleepiness 
(p < 0.001), McGill Quality of Life Questionnaire (McGILL 
QOL) (p < 0.001), SAQLI (p < 0.001), Chronic Respiratory 
Disease Questionnaire (CRDQ) – Fatigue (p < 0.001), Emo-
tional (p < 0.01), Mastery (p < 0.01), and SF-36 – Mental 
Health (p < 0.05), and Vitality (p < 0.01) scores with respect 
to use of NIV at 9 months of follow-up [85]. In a prospective 
6-week study, Newsom-Davis et al. noted an improvement 
in cognitive functions and no deterioration of anxiety or de-
pression measures in a group of nine ALS patients following 
the start of NIV [87].
Effect of NIV on disease progression
There is no evidence that NIV affects overall disease pro-
gression, as measured by the rate of ALS-FRS-r deterioration, 
or respiratory muscle weakness (RMW) progression [71, 81, 
85]. However, a slower decline in lung function seems to occur 
with the use of NIV in ALS patients. In particular, four studies 
have shown a decrease of the VC from 2.52% to 1.09%, 4.8% to 
3.5%, 2.92% to 0.5%, and 5.1% to 2.5% per month, respectively 
[68, 88–90]. The mechanism is unclear but is possibly related 
to an increased pulmonary and chest wall compliance along 
the NIV use [85]. These findings must be treated with caution, 
because a slower decrease of FVC has also been reported in 
patients without NIV after their FVC values decreased below 
55% of the predicted value [91].
Impact of NIV on caregivers
Mustfa et al. showed that caregivers of NIV patients 
(n = 21) had similar increase in burden than did caregivers of 
patients without indication for NIV (n = 10) [85]. 
Invasive ventilation (IV)
Patients require invasive ventilation once the need for 
NIV exceeds 23/24h or in a case of abundant salivary/upper 
respiratory tract secretions. 
The decision on tracheostomy should be taken in advance 
to ensure timeline planning of the procedure and to avoid 
performing it in an emergency situation [92]. Importantly, 
the decision to pursue IV involves an acceptance of further 
progress of the disease plausibly resulting in a complete loss 
of motor function. Eye movements are usually spared, but 
cases of full ophthalmoplegia in patients on long-term me-
chanical ventilation have been reported [93]. In a Japanese 
study, 13% of 709 ALS patients developed a full locked-in 
state, with the majority of them (70%) within five years of 
introducing IV [94]. 
Thus, to make an informed choice about IV, the patient 
must be aware of the risk that they might develop locked-in 
syndrome (LIS) and/or dementia. Unfortunately, a lack of 
informed consent prior to IV implementation is commonly 
reported, particularly in emergency situations. Based on data 
reported in eight studies, emergency introduction occurs in 
as many as 53% of cases [95–102].
Prevalence of IV
Predictors of a favourable attitude towards the use of IV 
are younger age, male gender, married status, having younger 
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children, the concurrent use of PEG, and a higher income 
[43, 103, 100, 104–108]. There was no influence of the site of 
disease onset [100, 104, 109]. Previous use of NIV is linked to 
a doubled chance of opting for IV [100, 109, 110]. The most 
relevant factors in the decision-making process include QoL, 
severity of disability, ability to return home, possibility of dis-
continuing mechanical ventilation if one chooses to do so, and 
concern about the QoL of one’s family [111]. Factors proposed 
to predict successful use of IV are: a highly motivated patient 
who is sensitive to the needs of his or her family and engaged in 
the family and/or the community; a slowly progressive course 
of the disease; a thorough understanding of the alternatives to 
IV; awareness of the progression of ALS and of the possibility 
of cognitive impairment; a well-informed family willing to 
assume the burdens of IV; financial resources for the support 
network (a healthcare-system-dependent factor); an advance 
directive for discontinuing IV; and the adaptability of both 
the patient and their family to constantly change caregivers, 
equipment, and limitations [112].
Globally, the usage of IV differs greatly due to different 
healthcare systems and cultural backgrounds [113]. It is rarely 
proposed in North America for example because the patient’s 
autonomy remains the core basis of management there [95, 113]. 
IV is common among Japanese patients where the deci-
sion-making is largely left to the physician who is commit-
ted to prolonging life [113]. Heterogeneous preferences are 
observed in Europe [113], with usages of 11.1%, 4%, and 1% 
in Scotland, Norway, and Ireland, respectively [54, 114, 115]. 
It is worth noting that a significantly higher rate is observed 
in patients who are under the care of a respiratory care unit 
(50%) [99].
Effect of IV on survival
Obviously, the support of IV results in longer survival in 
ALS patients versus individuals who refuse respiratory sup-
port. Spataro et al. showed a longer median survival (47 vs 
31 months, p = 0.008) in patients who chose IV (n = 87) 
compared to those who refused tracheostomy (n = 192) [104]. 
The mean survival in patients on IV ranges from eight 
months to five years [100, 101, 104, 116]. In a 10-year popu-
lation-based study of 1,260 Italian ALS patients, the overall 
one-year, three-year, and five-year survival rates on IV were 
42.6% (SE 4.3%), 22.9% (SE 3.8%), and 12.2% (SE 3.3%), 
respectively [100]. 
Older age (> 60–65), bulbar onset, a lower ALSFRS-r score 
(< 11), no concurrent use of PEG, a lower FVC at baseline, and 
a single/divorced/widowed status are related to significantly 
shorter survival in patients using IV [100, 101, 103, 104, 
109, 117]. Importantly, concomitant chronic diseases have 
no influence on the outcome of IV [118]. In a recent study, 
a steeper BMI decrease prior to the start of IV was related to 
a significantly faster progression of motor disabilities, includ-
ing ophthalmoplegia, total quadriplegia, and mouth-opening 
ability after IV placement [119].
Any deterioration of the clinical state of patients on IV is 
mainly related to pneumonia, rapidly progressive dyspnoea, 
nocturnal seizure, or following routine general anaesthesia [118].
The main causes of death in ALS patients using IV are 
broncho-pneumonia (29%), hypoxia (25%), aspiration pneu-
monia (19%), pulmonary embolism (7.5%), and cardiac 
ischaemia (1%) [82]. 
Effect of IV on QoL
Contrary to the general perception of IV as a significant 
burden on the patient, there is complete agreement in the 
literature that no significant deterioration in QoL occurs due 
to the use of IV in ALS patients. In particular, Kaub-Wittemer 
et al. found no significant differences between patients on NIV 
and IV with regard to the Profile of Mood States (POMS) that 
assesses feelings and emotional states, and the Munich Quality 
of Life Dimensions List (MLDL) that evaluates satisfaction 
with one’s physical condition, psyche, social life, and everyday 
life [97]. Vianello et al. observed a similar prevalence in the 
use of anti-depressant drugs and the mean Beck Depression 
Inventory (BDI) and 11-item short-form Life Satisfaction 
Index (LSI-11) scores in patients with IV compared to those 
without IV [101]. In agreement with these findings, in a study 
involving 19 patients in LIS (17 on IV, two on NIV) found that 
most showed no clinically relevant signs of depression (74%), 
or wish for hastened death (90%), and stated that they would 
opt for mechanical ventilation again (90%) [16]. Rousseau 
et al. detected comparable scores on the 36-item Short Form 
Health Survey (SF-36) aimed at assessing overall health status 
and QoL, in non-LIS and LIS patients with regard to the use 
of IV [120]. Importantly, no difference was found between 
patients on NIV and IV with regard to choosing again or rec-
ommending their current type of ventilation to other patients 
(94% vs 81% and 88% vs 81%, respectively) [97].
Impact of IV on caregivers
Despite the possible benefits of IV for ALS patients, such 
a decision usually brings with it an important financial and 
care burden for caregivers.
In a study that followed 71 caregivers until the death or 
tracheostomy of the patient, a higher prevalence of depression 
at baseline was noted in caregivers of patients who eventually 
opted for IV than in those whose proxies died (50% vs 16%). 
In both situations, the depression rate declined over time (8.3% 
vs 10.5%, respectively) after the IV or death of the patient 
[108]. Among eight caregivers who were interviewed after the 
patients’ tracheostomies, the burden score increased in five, 
remained stable in two, and declined in one [107]. Although 
Kaub-Wittemer et al. found comparable results for POMS and 
MLDL between caregivers of NIV and IV patients [97], there 
was a strong disagreement with regard to NIV and IV when 
asked if they would advice their patient to choose ventilation 
again (97% vs 75%, p = 0.008) [97]. In this study, 30% of 
caregivers rated their own overall QoL as lower than that of 
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their respective patient [97]. Similar findings were reported by 
Linse et al. in a study in which caregivers rated their own QoL 
and their perceived QoL of their patient as being significantly 
lower than the actual QoL of the patient [121]. 
These findings agree with other studies showing that 
healthy individuals and caregivers perceive the QoL of the 
patients to be lower, while depression is higher compared 
to the patients themselves [16, 122]. This phenomenon has 
also been found among physicians, whose correct perception 
of a patient’s psychological status depends on their years of 
experience [123]. 
A summary of the studies on the use of gastrostomy, 
NIV and IV is presented in supplementary Tables 3, 4 and 
5, respectively.
Discussion
The optimal management of patients with ALS requires the 
protection of autonomy, the improvement or maintenance of 
QoL, and, importantly, the provision of information in advance 
of deterioration, especially regarding respiratory failure [118]. 
Ad hoc decisions lead to poorer outcomes in ALS patients. 
A discussion with a patient should address all the relevant 
domains of the therapeutic options, including benefits, risks 
or constraints, and consequences.
Gastrostomy tube feeding is a useful way of providing 
nutrition to ALS patients. While the evidence of its effect 
on survival and QoL is insufficient, improvements in certain 
domains of life are commonly reported. Due to a strong as-
sociation between weight loss and a poor outcome in ALS, 
enteral tube feeding may indirectly have a positive influence 
on disease outcome by securing the body mass and preventing 
escalation of muscle wasting.
Overall, there is agreement in the literature about the 
positive effect that NIV has on patients’ survival and QoL. 
Moreover, NIV remains an effective palliative treatment for 
symptoms induced by hypoventilation and sleep disturbance. 
Earlier implementation of NIV seems to result in a greater 
benefit. 
IV is related to longer survival in ALS, but is introduced 
in emergency situations in up to 50% of cases, mainly due to 
a lack of prior informed consent and appropriate discussions. 
Contrary to expectations, no significant deterioration in QoL 
has been observed in IV patients, including even those in 
a locked-in state. 
PEG and NIV have not been found to impact upon the 
burden on caregivers. Conversely, IV has been found to impose 
a huge burden on caregivers. Indeed, caregivers have expressed 
a more negative attitude towards IV than patients, although 
from the time of IV placement there is no further deterioration 
in QoL for the majority of caregivers.
Comorbid cognitive impairment and neurobehavioural 
dysfunction affect up to 50% of patients with ALS, and reduce 
the efficacy of life-prolonging therapies. These issues mainly 
affect survival outcome because compliance is rarely achieved 
under such circumstances [57]. Thus, this group of patients 
requires more insightful care and monitoring. 
In addition, the care of patients with ALS may involve 
exit strategies such as continuous deep sedation (CDS), phy-
sician-assisted suicide (PAS), or euthanasia. Because these 
strategies are not legal in most countries, only a few studies 
have investigated these issues. Generally, the wish for hastened 
death is low even in LIS patients, and declines over the course 
of the disease, possibly due to the adaptation process [16]. The 
frequency of PAS or euthanasia is low among patients with 
ALS, ranging from 5% in Germany and Switzerland to 20% 
in the Netherlands [124–128]. In Dutch patients, the main 
reasons for life-ceasing therapy are the lack of a chance for 
improvement, being dependent on others, fear of choking, 
fatigue and loss of dignity [124]. 
In conclusion, PEG and NIV are beneficial therapeutic 
options for ALS patients, while IV may be a reasonable option 
for some individuals. Timely discussions of these medical 
interventions should be undertaken to ensure informed and 
autonomous decision-making regarding their future use. 
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